The proposed late‐stage pro‐metastatic functions of NRAS are compatible with its proposed impact across bodily tumor types and adds potential clinical value to the findings, implying it can be a marked therapeutic target against lung metastases from any tumor, regardless of the divergent mechanisms employed by different cancers to gain access to the vasculature (Rafii et al, 2002; Valastyan & Weinberg, 2011; Vanharanta & Massague, 2013). This evidence concerns the gene NRAS and cancer.